Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

PET Imaging of Liposomal Glucocorticoids using 89Zr-oxine: Theranostic Applications in Inflammatory Arthritis.

Gawne PJ, Clarke F, Turjeman K, Cope AP, Long NJ, Barenholz Y, Terry SYA, de Rosales RTM.

Theranostics. 2020 Feb 26;10(9):3867-3879. doi: 10.7150/thno.40403. eCollection 2020.

2.

Phosphatase PTPN22 Regulates Dendritic Cell Homeostasis and cDC2 Dependent T Cell Responses.

Purvis HA, Clarke F, Montgomery AB, Colas C, Bibby JA, Cornish GH, Dai X, Dudziak D, Rawlings DJ, Zamoyska R, Guermonprez P, Cope AP.

Front Immunol. 2020 Mar 4;11:376. doi: 10.3389/fimmu.2020.00376. eCollection 2020.

3.

PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.

Knipper JA, Wright D, Cope AP, Malissen B, Zamoyska R.

Front Immunol. 2020 Jan 28;11:52. doi: 10.3389/fimmu.2020.00052. eCollection 2020.

4.

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.

Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB.

Rheumatology (Oxford). 2020 Jan 30. pii: kez671. doi: 10.1093/rheumatology/kez671. [Epub ahead of print]

PMID:
31998962
5.

Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.

Traylor M, Knevel R, Cui J, Taylor J, Harm-Jan W, Conaghan PG, Cope AP, Curtis C, Emery P, Newhouse S, Patel H, Steer S, Gregersen P, Shadick NA, Weinblatt ME, Van Der Helm-van Mil A, Barrett JH, Morgan AW, Lewis CM, Scott IC.

PLoS One. 2019 Oct 9;14(10):e0223246. doi: 10.1371/journal.pone.0223246. eCollection 2019.

6.

Differential nanoscale organisation of LFA-1 modulates T-cell migration.

Shannon MJ, Pineau J, Griffié J, Aaron J, Peel T, Williamson DJ, Zamoyska R, Cope AP, Cornish GH, Owen DM.

J Cell Sci. 2019 Oct 16;133(5). pii: jcs232991. doi: 10.1242/jcs.232991.

PMID:
31471459
7.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

8.

Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies.

Cope AP.

Clin Ther. 2019 Jul;41(7):1299-1311. doi: 10.1016/j.clinthera.2019.04.014. Epub 2019 Jun 10.

PMID:
31196650
9.

Placebo Response in Rheumatoid Arthritis Clinical Trials.

Bechman K, Yates M, Norton S, Cope AP, Galloway JB.

J Rheumatol. 2020 Jan;47(1):28-34. doi: 10.3899/jrheum.190008. Epub 2019 May 1.

PMID:
31043548
10.

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2019 Oct 1;58(10):1767-1776. doi: 10.1093/rheumatology/kez037.

PMID:
30982886
11.

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.

Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB.

Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087.

PMID:
30982883
12.

Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis.

Gullick NJ, Ibrahim F, Scott IC, Vincent A, Cope AP, Garrood T, Panayi GS, Scott DL, Kirkham BW; TITRATE Programme Investigators.

BMC Rheumatol. 2019 Feb 25;3:6. doi: 10.1186/s41927-019-0054-y. eCollection 2019.

13.

The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells.

Perucha E, Melchiotti R, Bibby JA, Wu W, Frederiksen KS, Roberts CA, Hall Z, LeFriec G, Robertson KA, Lavender P, Gerwien JG, Taams LS, Griffin JL, de Rinaldis E, van Baarsen LGM, Kemper C, Ghazal P, Cope AP.

Nat Commun. 2019 Jan 30;10(1):498. doi: 10.1038/s41467-019-08332-9.

14.

The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.

Scott IC, Ibrahim F, Panayi G, Cope AP, Garrood T, Vincent A, Scott DL, Kirkham B; TITRATE Programme Investigators.

Semin Arthritis Rheum. 2019 Aug;49(1):20-26. doi: 10.1016/j.semarthrit.2018.12.006. Epub 2018 Dec 28.

PMID:
30685064
15.

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.

Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY.

J Rheumatol. 2018 Nov;45(11):1515-1521. doi: 10.3899/jrheum.171375. Epub 2018 Sep 1.

16.

The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.

Clarke F, Purvis HA, Sanchez-Blanco C, Gutiérrez-Martinez E, Cornish GH, Zamoyska R, Guermonprez P, Cope AP.

Sci Rep. 2018 Aug 23;8(1):12692. doi: 10.1038/s41598-018-31179-x.

17.

Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses.

Sanchez-Blanco C, Clarke F, Cornish GH, Depoil D, Thompson SJ, Dai X, Rawlings DJ, Dustin ML, Zamoyska R, Cope AP, Purvis HA.

J Autoimmun. 2018 Nov;94:45-55. doi: 10.1016/j.jaut.2018.07.008. Epub 2018 Jul 24.

18.

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC, Bongartz T, Massey J, Mifsud B, Spiliopoulou A, Scott IC, Wang J, Morgan M, Plant D, Colombo M, Orchard P, Twigg S, McInnes IB, Porter D, Freeston JE, Nam JL, Cordell HJ, Isaacs JD, Strathdee JL, Arnett D, de Hair MJH, Tak PP, Aslibekyan S, van Vollenhoven RF, Padyukov L, Bridges SL, Pitzalis C, Cope AP, Verstappen SMM, Emery P, Barnes MR, Agakov F, McKeigue P, Mushiroda T, Kubo M, Weinshilboum R, Barton A, Morgan AW, Barrett JH; MATURA; and PAMERA; Consortia.

Pharmacogenomics J. 2018 Jul;18(4):528-538. doi: 10.1038/s41397-018-0025-5. Epub 2018 May 25. Review.

19.

Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus.

Lewis MJ, McAndrew MB, Wheeler C, Workman N, Agashe P, Koopmann J, Uddin E, Morris DL, Zou L, Stark R, Anson J, Cope AP, Vyse TJ.

J Autoimmun. 2018 Jul;91:1-12. doi: 10.1016/j.jaut.2018.02.009. Epub 2018 Mar 22.

PMID:
29576246
20.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
21.

Emerging therapies for pre-RA.

Cope AP.

Best Pract Res Clin Rheumatol. 2017 Feb;31(1):99-111. doi: 10.1016/j.berh.2017.08.005. Epub 2017 Sep 11. Review.

PMID:
29221603
22.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

23.

Protein tyrosine phosphatase PTPN22 is dispensable for dendritic cell antigen processing and promotion of T-cell activation by dendritic cells.

Clarke F, Jordan CK, Gutiérrez-Martinez E, Bibby JA, Sanchez-Blanco C, Cornish GH, Dai X, Rawlings DJ, Zamoyska R, Guermonprez P, Cope AP, Purvis HA.

PLoS One. 2017 Oct 17;12(10):e0186625. doi: 10.1371/journal.pone.0186625. eCollection 2017.

24.

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL.

Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315.

25.

Protein tyrosine phosphatase PTPN22 regulates IL-1β dependent Th17 responses by modulating dectin-1 signaling in mice.

Purvis HA, Clarke F, Jordan CK, Blanco CS, Cornish GH, Dai X, Rawlings DJ, Zamoyska R, Cope AP.

Eur J Immunol. 2018 Feb;48(2):306-315. doi: 10.1002/eji.201747092. Epub 2017 Oct 20.

26.

3D Bayesian cluster analysis of super-resolution data reveals LAT recruitment to the T cell synapse.

Griffié J, Shlomovich L, Williamson DJ, Shannon M, Aaron J, Khuon S, L Burn G, Boelen L, Peters R, Cope AP, Cohen EAK, Rubin-Delanchy P, Owen DM.

Sci Rep. 2017 Jun 22;7(1):4077. doi: 10.1038/s41598-017-04450-w.

27.

Genetic and environmental risk factors for rheumatoid arthritis in a UK African ancestry population: the GENRA case-control study.

Traylor M, Curtis C, Patel H, Breen G, Hyuck Lee S, Xu X, Newhouse S, Dobson R, Steer S, Cope AP, Markus HS, Lewis CM, Scott IC.

Rheumatology (Oxford). 2017 Aug 1;56(8):1282-1292. doi: 10.1093/rheumatology/kex048.

28.

The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis.

Euesden J, Matcham F, Hotopf M, Steer S, Cope AP, Lewis CM, Scott IC.

Psychosom Med. 2017 Jul/Aug;79(6):638-645. doi: 10.1097/PSY.0000000000000462.

29.

Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of αvβ3 Integrin Expression with Gallium-68.

Imberti C, Terry SY, Cullinane C, Clarke F, Cornish GH, Ramakrishnan NK, Roselt P, Cope AP, Hicks RJ, Blower PJ, Ma MT.

Bioconjug Chem. 2017 Feb 15;28(2):481-495. doi: 10.1021/acs.bioconjchem.6b00621. Epub 2016 Dec 14.

30.

A Bayesian cluster analysis method for single-molecule localization microscopy data.

Griffié J, Shannon M, Bromley CL, Boelen L, Burn GL, Williamson DJ, Heard NA, Cope AP, Owen DM, Rubin-Delanchy P.

Nat Protoc. 2016 Dec;11(12):2499-2514. doi: 10.1038/nprot.2016.149. Epub 2016 Nov 17.

31.

Superresolution imaging of the cytoplasmic phosphatase PTPN22 links integrin-mediated T cell adhesion with autoimmunity.

Burn GL, Cornish GH, Potrzebowska K, Samuelsson M, Griffié J, Minoughan S, Yates M, Ashdown G, Pernodet N, Morrison VL, Sanchez-Blanco C, Purvis H, Clarke F, Brownlie RJ, Vyse TJ, Zamoyska R, Owen DM, Svensson LM, Cope AP.

Sci Signal. 2016 Oct 4;9(448):ra99.

PMID:
27703032
32.

T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells.

Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, Dutow P, Woodruff TM, Yu ZX, O'Neill LA, Coll RC, Sher A, Leonard WJ, Köhl J, Monk P, Cooper MA, Arno M, Afzali B, Lachmann HJ, Cope AP, Mayer-Barber KD, Kemper C.

Science. 2016 Jun 17;352(6292):aad1210. doi: 10.1126/science.aad1210.

33.

Bayesian cluster identification in single-molecule localization microscopy data.

Rubin-Delanchy P, Burn GL, Griffié J, Williamson DJ, Heard NA, Cope AP, Owen DM.

Nat Methods. 2015 Nov;12(11):1072-6. doi: 10.1038/nmeth.3612. Epub 2015 Oct 5.

34.

Correction. Immunoglobulin light chain allelic inclusion in systemic lupus erythematosus.

Fraser LD, Zhao Y, Lutalo PM, D'Cruz DP, Cason J, Silva JS, Dunn-Walters DK, Nayar S, Cope AP, Spencer J.

Eur J Immunol. 2015 Sep;45(9):2701. doi: 10.1002/eji.201570097. No abstract available.

35.

Immunoglobulin light chain allelic inclusion in systemic lupus erythematosus.

Fraser LD, Zhao Y, Lutalo PM, D'Cruz DP, Cason J, Silva JS, Dunn-Walters DK, Nayar S, Cope AP, Spencer J.

Eur J Immunol. 2015 Aug;45(8):2409-19. doi: 10.1002/eji.201545599. Epub 2015 Jun 24. Erratum in: Eur J Immunol. 2015 Sep;45(9):2701.

36.

The ying and yang of fever in rheumatic disease.

Galloway J, Cope AP.

Clin Med (Lond). 2015 Jun;15(3):288-91. doi: 10.7861/clinmedicine.15-3-288.

37.

Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?

Scott IC, Rijsdijk F, Walker J, Quist J, Spain SL, Tan R, Steer S, Okada Y, Raychaudhuri S, Cope AP, Lewis CM.

J Rheumatol. 2015 Jul;42(7):1131-40. doi: 10.3899/jrheum.141211. Epub 2015 May 15.

38.

Improving medication adherence in rheumatoid arthritis (RA): a pilot study.

Ferguson A, Ibrahim FA, Thomas V, Weinman J, Simpson C, Cope AP, Scott DL, Lempp H.

Psychol Health Med. 2015;20(7):781-9. doi: 10.1080/13548506.2015.1009917. Epub 2015 Mar 16.

PMID:
25774559
39.

Immunoglobulin kappa variable region gene selection during early human B cell development in health and systemic lupus erythematosus.

Hehle V, Fraser LD, Tahir R, Kipling D, Wu YC, Lutalo PM, Cason J, Choong L, D'Cruz DP, Cope AP, Dunn-Walters DK, Spencer J.

Mol Immunol. 2015 Jun;65(2):215-23. doi: 10.1016/j.molimm.2015.01.017. Epub 2015 Feb 17.

PMID:
25700344
40.

Topographic prominence as a method for cluster identification in single-molecule localisation data.

Griffié J, Boelen L, Burn G, Cope AP, Owen DM.

J Biophotonics. 2015 Nov;8(11-12):925-34. doi: 10.1002/jbio.201400127. Epub 2015 Feb 6.

PMID:
25663080
41.

Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.

Ma MH, Scott IC, Dahanayake C, Cope AP, Scott DL.

J Rheumatol. 2014 Jul;41(7):1298-303. doi: 10.3899/jrheum.131401.

PMID:
24931951
42.

TNF-α blockade induces IL-10 expression in human CD4+ T cells.

Evans HG, Roostalu U, Walter GJ, Gullick NJ, Frederiksen KS, Roberts CA, Sumner J, Baeten DL, Gerwien JG, Cope AP, Geissmann F, Kirkham BW, Taams LS.

Nat Commun. 2014;5:3199. doi: 10.1038/ncomms4199.

43.

ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.

Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, Scott IC.

Arthritis Res Ther. 2014 Jan 16;16(1):R13. doi: 10.1186/ar4439.

44.

Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.

Scott IC, Seegobin SD, Steer S, Tan R, Forabosco P, Hinks A, Eyre S, Morgan AW, Wilson AG, Hocking LJ, Wordsworth P, Barton A, Worthington J, Cope AP, Lewis CM.

PLoS Genet. 2013;9(9):e1003808. doi: 10.1371/journal.pgen.1003808. Epub 2013 Sep 19. Erratum in: PLoS Genet. 2013 Oct;9(10). doi:10.1371/annotation/a86ab397-f58c-4144-a241-4957836a728a.

45.

CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner.

Afzali B, Mitchell PJ, Edozie FC, Povoleri GA, Dowson SE, Demandt L, Walter G, Canavan JB, Scotta C, Menon B, Chana PS, Khamri W, Kordasti SY, Heck S, Grimbacher B, Tree T, Cope AP, Taams LS, Lechler RI, John S, Lombardi G.

Eur J Immunol. 2013 Aug;43(8):2043-54. doi: 10.1002/eji.201243296. Epub 2013 Jul 3.

46.

Adding new perspectives to the kaleidoscope of remission criteria in rheumatoid arthritis.

Ma MH, Cope AP, Scott DL.

J Rheumatol. 2013 Apr;40(4):353-5. doi: 10.3899/jrheum.130099. No abstract available.

PMID:
23547254
47.

The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis.

Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP.

Rheumatology (Oxford). 2013 May;52(5):856-67. doi: 10.1093/rheumatology/kes376. Epub 2013 Jan 3. Review.

PMID:
23287363
48.

Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.

Walter GJ, Evans HG, Menon B, Gullick NJ, Kirkham BW, Cope AP, Geissmann F, Taams LS.

Arthritis Rheum. 2013 Mar;65(3):627-38. doi: 10.1002/art.37832.

49.

Signal transduction pathways in chronic inflammatory rheumatic diseases.

Cope AP.

Open Rheumatol J. 2012;6:207-8. Epub 2012 Sep 7. No abstract available.

50.

Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation.

Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, Williams LM, Cope AP, Horwood NJ.

PLoS One. 2012;7(7):e39871. doi: 10.1371/journal.pone.0039871. Epub 2012 Jul 3.

Supplemental Content

Support Center